ArticleInfection and immunity2006
Topical application of Escherichia coli-vectored vaccine as a simple method for eliciting protective immunity.
Article in Infection and immunity, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 31 citations in OpenAlex.
- Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction againstFrontiers in immunology · 2023Article
- An Engineered Outer Membrane-DefectiveJournal of microbiology and biotechnology · 2022Article
- Transcutaneous Administration of Dengue Vaccines.Viruses · 2020Article
- Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions.Veterinary research · 2018Review
- Leaf-Encapsulated Vaccines: Agroinfiltration and Transient Expression of the AntigenJournal of immunology research · 2018Article
- Vaccination with Killed but Metabolically ActiveJournal of nature and science · 2017Article
- Noninvasive vaccination as a casus belli to redeem vaccine value in the face of anti-vaccine movements.Integrative molecular medicine · 2017Article
- A trail blazed through DNA vaccine, noninvasive vaccine, and innate-adaptive immunity duo.Human vaccines & immunotherapeutics · 2014Article
- Transcutaneous antigen delivery system.BMB reports · 2013Review
- An adenovirus-vectored nasal vaccine confers rapid and sustained protection against anthrax in a single-dose regimen.Clinical and vaccine immunology : CVI · 2013Article
- Article
- One-pot bio-synthesis: N-acetyl-D-neuraminic acid production by a powerful engineered whole-cell catalyst.Scientific reports · 2011Article
- Article
- Article
- Proteomics integrated with Escherichia coli vector-based vaccines and antigen microarrays reveals the immunogenicity of a surface sialidase-like protein of Propionibacterium acnes.Proteomics. Clinical applications · 2008Article
- A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.Protein expression and purification · 2008Article
- Topical vaccination: the skin as a unique portal to adaptive immune responses.Seminars in immunopathology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We report here that animals can be protected against lethal infection by Clostridium tetani cells and Bacillus anthracis spores following topical application of intact particles of live or gamma-irradiated Escherichia coli vectors overproducing tetanus and anthrax antigens, respectively. Cutaneous gammadeltaT cells were rapidly recruited to the administration site. Live E. coli cells were not found in nonskin tissues after topical application, although fragments of E. coli DNA were disseminated transiently. Evidence suggested that intact E. coli particles in the outer layer of skin may be disrupted by a gammadeltaT-cell-mediated innate defense mechanism, followed by the presentation of E. coli ligand-adjuvanted intravector antigens to the immune system and rapid degradation of E. coli components. The nonreplicating E. coli vector overproducing an exogenous immunogen may foster the development of a new generation of vaccines that can be manufactured rapidly and administered noninvasively in a wide variety of disease settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.